Cellular Biomedicine Group (NASDAQ:CBMG) and Krystal Biotech (NASDAQ:KRYS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, earnings, analyst recommendations and dividends.
Insider & Institutional Ownership
22.0% of Cellular Biomedicine Group shares are owned by institutional investors. Comparatively, 73.1% of Krystal Biotech shares are owned by institutional investors. 8.5% of Cellular Biomedicine Group shares are owned by company insiders. Comparatively, 27.4% of Krystal Biotech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for Cellular Biomedicine Group and Krystal Biotech, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
|---|
| Cellular Biomedicine Group | 0 | 2 | 0 | 0 | 2.00 |
| Krystal Biotech | 0 | 0 | 5 | 0 | 3.00 |
Cellular Biomedicine Group presently has a consensus price target of $19.00, suggesting a potential upside of 5.09%. Krystal Biotech has a consensus price target of $97.25, suggesting a potential upside of 39.79%. Given Krystal Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Krystal Biotech is more favorable than Cellular Biomedicine Group.
Earnings & Valuation
This table compares Cellular Biomedicine Group and Krystal Biotech's revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
|---|
| Cellular Biomedicine Group | $340,000.00 | 1,035.77 | $-49,980,000.00 | N/A | N/A |
| Krystal Biotech | N/A | N/A | $-19,090,000.00 | ($1.20) | -57.98 |
Krystal Biotech has lower revenue, but higher earnings than Cellular Biomedicine Group.
Risk & Volatility
Cellular Biomedicine Group has a beta of 1.35, indicating that its share price is 35% more volatile than the S&P 500. Comparatively, Krystal Biotech has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500.
Profitability
This table compares Cellular Biomedicine Group and Krystal Biotech's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
|---|
| Cellular Biomedicine Group | N/A | -144.80% | -61.68% |
| Krystal Biotech | N/A | -10.72% | -10.40% |
Summary
Krystal Biotech beats Cellular Biomedicine Group on 8 of the 11 factors compared between the two stocks.
